Publication | Closed Access

N-arylpiperazine-containing compound (C2): An enhancer of sunitinib in the treatment of pancreatic cancer, involving D1DR activation

Medicinal ChemistryPancreatic CancerD1dr ActivationMedicinePharmacologyPharmacotherapyN-arylpiperazine-containing CompoundAnti-cancer AgentCancer TreatmentOncologyRadiation OncologyCancer ResearchDrug Discovery